Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder

Abstract

The gut microbiome is a heterogeneous population of microbes comprising viruses, bacteria, fungi, and protozoa. Such a microbiome is essential for sustaining host equilibrium, and its impact on human health can be altered by a variety of factors such as external variables, social behavior, age, nutrition, and genetics. Gut microbes’ imbalances are related to a variety of chronic diseases including cancer, obesity, and digestive disorders. Globally, recent findings show that intestinal microbes have a significant role in the formation of cardiovascular disease (CVD), which is still the primary cause of fatalities. Atherosclerosis, hypertension, diabetes, inflammation, and some inherited variables are all cardiovascular risk variables. However, studies found correlations between metabolism, intestinal flora, and dietary intake. Variations in the diversity of gut microbes and changes in their activity are thought to influence CVD etiology. Furthermore, the gut microbiota acts as an endocrine organ, producing bioactive metabolites such as TMA (trimethylamine)/TMAO (trimethylamine N-oxide), SCFA (short-chain fatty acids), and bile acids, which have a substantial impact on host wellness and disease by multiple mechanisms. The purpose of this overview is to compile current evidence highlighting the intricate links between gut microbiota, metabolites, and the development of CVD. It focuses on how intestinal dysbiosis promotes CVD risk factors such as heart failure, hypertension, and atherosclerosis. This review explores the normal physiology of intestinal microbes and potential techniques for targeting gut bacteria for CVD treatment using various microbial metabolites. It also examines the significance of gut bacteria in disease treatment, including supplements, prebiotics, probiotics, antibiotic therapies, and fecal transplantation, which is an innovative approach to the management of CVD. As a result, gut bacteria and metabolic pathways become increasingly attractive as potential targets for CVD intervention.

Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson’s Disease—A Narrative Review

“…Beneficial effects of FMT include preserved intestinal barrier function, improved intestinal motility, production of SCFA or a reduced number of pro-inflammatory bacterial strains in the gut [ 181 , 182 , 183 ]. The potential benefit of FMT was reported, e.g., in obesity, cardiovascular disorders, epilepsy and cognitive impairment [ 184 , 185 , 186 , 187 ]. In the animal MPTP model of PD, FMT was shown to improve the composition of the gut microbiota, decrease α-synuclein expression, inhibit microglial activation in SN, block pro-inflammatory signaling pathways and reduce behavioral changes [ 188 , 189 ].…”

Paradoxes: Cholesterol and Hypoxia in Preeclampsia

“…A meta-analysis of nine studies using olive oil supplementation also showed reduced risk of preeclampsia [208]. Increased dietary fiber has consistently shown reduced preeclampsia risk [209] perhaps through the mechanism of improving gut dysbiosis and increasing production of short chain saturated fatty acids [210] [211] [212] . Supplementation of omega-3 fatty acids has had mixed results with initial studies showing no benefit, but a 2018 Cochran meta-analysis showing possible reduction of preeclampsia risk with a relative risk of 0.84 in general population with low quality evidence, but significant protection among women with high risk [213] .…”

Atherosclerosis and Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside—Part 1

“…Some of the trials on the atheroprotective effects of anti-inflammatory agents are summarized in Table 2. In the conundrum of atherosclerosis there are risk-enhancing factors such as Lp(a) [89,90] and the microbiome [91,92]. Lp(a) seems to be the strongest independent genetic risk factor for myocardial infarction and aortic stenosis [93] and is associated to increased mortality [94].…”